SARS-CoV-2 Spike Protein Binding Molecule for Specific Infection Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs are not specific to SARS-COV-2, resulting in limited therapeutic effects and the inability to develop a specific drug for COVID-19, necessitating a targeted approach to address the virus effectively.
Innovation Solution
A SARS-COV-2 spike protein binding molecule is developed, comprising immunoglobulin single variable domains with specific CDR sequences and an immunoglobulin Fc region, which binds specifically to the SARS-COV-2 spike protein, blocking its interaction with the ACE2 receptor and inhibiting infection and amplification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum small-molecule antiviral drugs (remdesivir, favipiravir) are used, then they have a certain curative effect on COVID-19, but they lack specificity for SARS-COV-2 and the therapeutic effect is limited
Solution Approach 1:
The patent designs antibodies with specifically tailored CDR sequences that are optimized to recognize and bind to the SARS-COV-2 spike protein. By localizing the binding specificity to the CDR regions (particularly CDR3 which contacts the antigen), the antibody achieves high specificity for SARS-COV-2 while maintaining therapeutic efficacy. This resolves the contradiction by making the therapeutic agent locally specialized rather than broadly acting.
Solution Approach 2:
The patent systematically varies the CDR sequences to create different antibody variants with optimized binding characteristics. By changing the amino acid sequences in the CDR regions, the antibody's affinity and specificity for the SARS-COV-2 spike protein are enhanced. This parameter optimization allows the antibody to achieve both high therapeutic effect and high specificity, resolving the contradiction between these two properties.
2Ease of manufacture
If existing antiviral drugs are used, then treatment can be provided, but it is difficult to develop a specific drug for SARS-COV-2
Solution Approach 1:
The patent performs preliminary design and optimization of the antibody structure, particularly the CDR sequences, before production. By pre-optimizing the binding specificity and affinity through rational design and screening, the antibody is prepared in advance with the required characteristics for effective SARS-COV-2 treatment. This preliminary optimization ensures both manufacturability and high specificity, resolving the contradiction between ease of manufacture and treatment reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SARS-COV-2 spike protein binding molecule effectively blocks the virus's entry into human cells, demonstrating high specificity, stability, and biological activity with no toxic side effects, thereby inhibiting the infection and amplification of SARS-COV-2.
Implementation Method 1
A SARS-COV-2 spike protein binding molecule is developed, comprising immunoglobulin single variable domains with specific CDR sequences and an immunoglobulin Fc region, which binds specifically to the SARS-COV-2 spike protein, blocking its interaction with the ACE2 receptor
Data Source
AI summary
Provided are a SARS-COV-2 spike protein binding molecule and an application thereof. The binding molecule may specifically bind to a SARS-COV-2 spike protein and contains at least one immunoglobulin single variable domain, may effectively block the binding of the SARS-COV-2-Spike protein to an ACE2 receptor of a human cell, thereby blocking the infection of the cell with SARS-COV-2 and inhibiting SARS-COV-2 infection and amplification.